POST-DOCTORAL FELLOW IN ACUTE MYELOID LEUKEMIA RESEARCH
Host team & institute: BENAJIBA team - Identification and targeting of extrinsic regulators of myeloid malignancies - INSERM U944 - Saint-Louis Research Institute
Saint-Louis Research Institute was created in 1958 by Jean Bernard and Jean Dausset (Nobel Prize), aiming to achieve excellence in research and teaching in the fields of hematology, oncology, cell biology, immunology, virology, genetics, and therapeutic biotechnologies. Our research institute is located in the center of Paris within the Saint-Louis campus and benefits from a close relationship and collaboration with Saint-Louis hospital . Since 2024, Saint-Louis Research Institute is the home of the ambitious "Leukemia Institute THEMA" (IHU) , which seeks to develop novel approaches to cure leukemia and associated disorders. Our research unit (UMR U944: genomes, cellular biology & therapeutics) has an internationally recognized research program with world-renowned leukemia researchers , such as Jean Soulier, Hugues de Thé, and Alexandre Puissant. Our team is focused on identification and targeting of extrinsic regulators of myeloid malignancies , and is currently composed of 3 principal investigators, 2 associated clinicians, 1 lab manager, 2 bio-informaticians, 3 research technicians, 2 post-doctoral fellows, 4 PhD students, and 3 Master students. The team works in close partnership with Saint-Louis Hospital Clinical Investigations Center to accelerate the clinical translation of our lab discoveries. Our team also benefits from a privileged access to primary patient samples and a large variety of institutional core facilities , including a fully equipped animal facility, a flow cytometry facility, a sequencing facility, and an imaging facility.
Available position: A one-year post-doctoral position (possible 2 years extension) is open in the team led by Dr. Lina BENAJIBA, a physician-scientist focusing on target identification and drug discovery in Acute Myeloid Leukemia. Starting date should be between November 2024 and March 2025.
We are looking for a highly motivated and dynamic fellow wishing to complete his post-doctoral training in a young and international ERC starting and ATIP-Avenir team . The candidate must appreciate teamwork , have good interpersonal skills, and be rigorous and organized in his/her work. Experience in molecular/cellular biology is required. Experience in murine models, functional screening, single cell RNA-seq, spatial transcriptomics, spatial proteomics, and microscopy would be an asset. Applicants should hold a PhD degree in Biochemistry, Cellular Biology, Molecular Biology, Oncology, Hematology or related disciplines (or have recently submitted their thesis with scheduled defense).
Project description: Our team develops translational research strategies focused on the identification of druggable oncogenic targets to pave the road for successful acute myeloid leukemia (AML) treatment. The post-doctoral fellow will seek to dissect the key role of the bone marrow (BM) niche in AML development, maintenance, and drug resistance, aiming ultimately to develop concomitant "seeds" and "soil" preventive and curative therapeutic strategies to improve patients' prognosis. Novel niche-hematopoietic crosstalk-induced dependencies will be unraveled using transcriptomic data combined to high-throughput functional screening methods in ectopic humanized in vivo BM-AML organoids. The post-doctoral fellow will then shed light on the mechanistic underpinnings of the BM-leukemia crosstalk using transcriptomic-, epigenomic-, and microscopy-based approaches.
Application Materials:
Cover letter explaining the candidate's interest in joining the lab and his/her future career development expectations (max 1 page).
Curriculum Vitae including academic track, main technical skills, main past achievements, and scientific productions.
Contact details of three past supervisors who can be contacted for recommendation letters.
#J-18808-Ljbffr